Zhou Yunshu's First Transaction After Taking Office: Why Did Xian Sheng Acquire a Land Parcel Pending Construction in Shanghai?

Publisher | China Visit Net

Review | Li Xiaoyan

On March 25, Simcere Pharmaceutical (02096.HK) officially announced two major moves: first, the appointment of Zhou Yunshu, former chairman of Hengrui Medicine, as the company’s Chief Executive Officer; second, the disclosure of a cash acquisition of 30.76 million yuan to buy 100% of the equity in Shanghai Simcere Diagnostics Technology Co., Ltd. As the first publicly disclosed transaction after Zhou Yunshu took office, this seemingly “lightweight” asset acquisition is, in fact, a key step for Simcere Pharmaceutical to deepen its layout on the innovative drug track and to connect industry-academia-research as well as internationalization. It carries the company’s ambition for strategic upgrading, while also drawing market attention due to the nature of the related-party transaction.

Simcere Pharmaceutical states that its indirectly wholly-owned subsidiary and its related party, Jiangsu Simcere Diagnostics Technology Co., Ltd., signed an agreement to acquire all equity interests in Shanghai Simcere Diagnostics for a transaction consideration of 30.76 million yuan. The target company was established in October 2021 and has no actual business operations. Its core assets are land-use rights for approximately 5,950.6 square meters of land in Huacao Town, Minhang District, Shanghai, with suspended in-progress construction works on the land. From a financial perspective, as of the end of 2025, Shanghai Simcere Diagnostics had total assets of 45.30 million yuan, total liabilities of 15.63 million yuan, and net assets of 29.67 million yuan. It recorded consecutive losses from 2023 to 2025 and had no revenue. The seller’s original acquisition cost was zero. The current pricing is based on an independent valuation report and was determined through fair negotiation. In terms of equity structure, the seller is wholly controlled by Jiangsu Medical Diagnostics, and 51.32% of the equity is wholly owned by Nanjing Qiyi, which is fully held by the couple Ren Yongfu and his wife as controlling shareholders of Simcere Pharmaceutical. Another 14.57% is wholly owned by Nanjing Xinjiyue, which is fully held by the couple Ren Jinsheng and his wife, the company’s executive director and chairman. The remaining 34.11% is owned by 26 institutional investors. In essence, this transaction injects the land assets held by family related parties of the controlling shareholder into the上市公司 structure.

Simcere Pharmaceutical makes clear that the acquisition’s core purpose is to build an open innovation exchange center. The center will shoulder three major strategic missions, closely aligning with the development path of the company’s innovation-driven approach, internationalization, and talent-based strong enterprise strategy. The center will serve as the hub for Simcere Pharmaceutical’s industrial incubation and transformation, attracting high-potential innovation entities to collaborate, introducing cutting-edge projects for incubation and implementation, and laying out unmet clinical needs and disruptive technologies. As Shanghai is a global hub for innovative biopharmaceuticals, with leading research institutions, startups, and capital concentrated there, the center can quickly connect with high-quality resources, shorten the cycle from laboratory research to industrialization, provide a source of fresh funding for replenishing the company’s pipeline, and fit Simcere’s business positioning with “innovative drugs as the core” (in 2025, innovative drugs accounted for 81.5% of revenue).

Choosing Minhang Huacao, adjacent to the Hongqiao International Open Hub, is a key consideration for this layout. The center will promote international pharmaceutical companies and R&D institutions to set up offices, facilitating deep integration between global R&D resources and China’s life science innovation ecosystem. Simcere Pharmaceutical is accelerating internationalization; it has previously advanced multiple overseas licensing projects. This center can become a “bridgehead” for it to connect international cooperation and to introduce overseas technologies and talent, helping support the upgrade of local pharmaceutical companies to multinational innovative drug companies. The announcement explicitly states that supporting living facilities will be built, aiming to address the severe constraints the Group faces in attracting and reserving high-end talent. With competition for high-end talent in the biopharmaceutical industry becoming increasingly intense, Shanghai’s high cost of living and tight availability of supporting resources are the pain points for enterprises in talent recruitment. The center will build a supporting system integrating residence and living services, and will form coordination with the R&D center that Simcere has already built in Minhang, thereby constructing a full-chain talent ecosystem of “R&D + incubation + living” to provide stability for innovation teams. In addition, the target land already has preliminary in-progress construction works. The acquisition can significantly shorten the construction timeline and reduce uncertainties, offering greater efficiency advantages than acquiring new land, meeting the needs for Simcere to quickly advance an innovation-oriented layout.

Zhou Yunshu has more than 30 years of experience in the pharmaceutical industry and previously led Hengrui Medicine’s innovative transformation. This time, as he becomes Simcere’s CEO, his first transaction immediately focuses on building an innovation ecosystem, sending a clear signal. On one hand, it reflects strategic focus: upon taking the role, he advances asset integration and directs resources toward innovation infrastructure, aligning with the core goal of Simcere’s “innovation upgrade,” and also consistent with his past experience in driving the development of companies’ R&D systems. On the other hand, it demonstrates execution capability: he quickly advances the implementation of the related-party transaction. It both completes the compliant injection of assets and clarifies the center’s strategic positioning, laying the foundation for subsequent operations and boosting market confidence in his management capabilities.

This transaction faces some market controversy because it involves related parties of the controlling shareholder’s family, and it should be viewed objectively. From a compliance perspective, Simcere Pharmaceutical has disclosed related-party transactions in accordance with the rules of the Hong Kong Exchanges and Clearing Limited. The pricing is based on an independent valuation report and determined through fair negotiation. The consideration of 30.76 million yuan is close to the target’s net assets of 29.67 million yuan. No obvious premium has been observed. Both the procedures and pricing meet regulatory requirements, and there is no suspicion of transferring interests. However, from potential risk angles, the target company has been loss-making consecutively with no revenue. The in-progress construction works on the land have been paused, and further capital will be needed to restart construction and improve supporting facilities. In the short term, this may create certain pressure on the company’s cash flow. Meanwhile, there is uncertainty regarding the effectiveness of the incubation and international collaboration of the innovation center. The actual attractiveness of talent support to talent also needs market validation. Moreover, although the related-party transaction is compliant, ongoing attention must still be paid to the company’s subsequent information disclosure and the efficiency of asset operations, to protect the interests of minority shareholders.

Currently, China’s innovative drug industry is moving from “pipeline competition” to “ecosystem competition.” Leading pharmaceutical companies are rolling out foundational infrastructure such as R&D centers, incubation platforms, and international cooperation hubs. Simcere Pharmaceutical’s land acquisition in Shanghai is precisely in line with industry trends. By leveraging Shanghai’s industrial, talent, and location advantages, the company is building a core node of an innovation ecosystem, synergizing with its existing R&D and commercialization system to strengthen long-term competitiveness. For Simcere, an investment of 30.76 million yuan may seem modest, yet it can unlock Shanghai’s innovative resources and provide support for innovative drug R&D, internationalization, and attracting and retaining talent—a typical layout of “a small input, a big strategy.”

Zhou Yunshu’s first transaction after taking office is an important milestone in Simcere Pharmaceutical’s strategic upgrade. The 30.76 million yuan acquisition of Shanghai land is not only a precise layout of the innovation ecosystem, but also a test of the compliance of the related-party transaction. From a positive perspective, the center will become a core carrier for Simcere to connect with global innovation, incubate frontier projects, and attract high-end talent, helping the company go steadily and far in the innovative drug space. From a prudent perspective, attention is needed for subsequent construction investments, operating efficiency, and transparency of the related-party transaction. As Zhou Yunshu fully takes the helm, Simcere Pharmaceutical’s innovation transformation and internationalization efforts are expected to accelerate. The strategic value of this “first deal” will gradually be realized in the future.